| Similar Articles |
 |
The Motley Fool September 27, 2006 Ralph Casale |
Qiagen: Biotech Support Is this biotech industry leader an attractive investment? While this is a quality company operating an attractive business, investors may want to wait for a better price before adding it to a portfolio.  |
The Motley Fool August 16, 2007 Brian Orelli |
More Drugmaker Growth Without the FDA All that high-tech lab equipment has to come from somewhere. Here's how investors can benefit from it, too.  |
Pharmaceutical Executive February 1, 2011 Jill Wechsler |
The Building Block of Drug Discovery With Francis Collins now calling the shots at NIH, will be be able to deliver on the innovations behind the genome?  |
Bio-IT World March 2007 Robert M. Frederickson |
The Market for Automation The QIAcube is a benchtop robotic system for fully automated sample preparation using the Qiagen spin-column kits that are currently in wide use.  |
Bio-IT World March 2006 Michael A. Greeley |
The Theranostics Promise A huge amount of discovery and clinical development for new drugs involves clinical trials that include companion diagnostic tests. These theranostic tests are poised to become a promising market for entrepreneurs, though challenges -- such as patent issues -- remain.  |
Bio-IT World January 12, 2004 Kevin Davies |
The Ultimate Platform Firm Greg Lucier on determinism in drug development at Invitrogen  |
Chemistry World March 16, 2011 |
Inspirational science Seong Keun Kim is head of the Molecular Reaction Dynamics Laboratory at Seoul National University, Korea. He uses spectroscopic, microscopic and computational methods to investigate a wide range of subjects from molecular physics and nanoscience to cell biology.  |
Bio-IT World August 13, 2002 Mark D. Uehling |
Clinical Trial Data Management: Tortured by Paper Reams of paper stuffed into boxes and shipped to the FDA by the truckload is hardly the best approach to drug approval. But what's the right way?  |
The Motley Fool December 30, 2003 Tom Taulli |
M&A As Strong Medicine Invitrogen's latest deal shows that the company knows where its market is headed.  |
The Motley Fool February 7, 2008 Brian Orelli |
Invitrogen Integrates After a rough 2006 in which it struggled to integrate its acquisitions, Invitrogen used 2007 to show why it made all of its purchases.  |
The Motley Fool August 17, 2007 Brian Orelli |
Fewer Drug Approvals? Buy! Stricter standards at the FDA could create a buying opportunity. Drug approvals are down one third this year, creating a lot of value in pharmaceutical and biotech companies. Just choose your medicines carefully.  |
HHMI Bulletin Nov 2011 Sarah C.P. Williams. |
Carolyn Bertozzi: Changed Expectations Chemists trained in biology were once a rarity -- now they're becoming the norm.  |
Bio-IT World January 21, 2005 |
How IT Can Decrease Time-to-Market in Clinical Trials Pharma manufacturers can learn from their industrial counterparts: Integrating systems can accelerate product delivery.  |
The Motley Fool January 31, 2006 Stephen D. Simpson |
Poring Over Millipore The life sciences R&D industry has room to grow. This stock price may not.  |
The Motley Fool February 16, 2010 Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.  |
Chemistry World June 17, 2015 Moray Stark |
Safe science: promoting a culture of safety in academic chemical research The drive for this timely book has been a number of serious, and sometimes fatal, accidents in US university chemistry labs.  |
The Motley Fool February 15, 2006 Stephen D. Simpson |
A Play on the Building Blocks of R&D Sigma-Aldrich might be suitable for those looking to play biological R&D without picking a specific pharma or biotech stock.  |
Bio-IT World September 2005 Bill Van Etten |
'If We Can Put a Man on the Moon . . .' Before the U.S. stops producing scientists, before we outlaw scientific research and knowledge altogether, scientists must make their best effort to bring science to the mainstream by familiarizing their children and their communities with who they are and what they do.  |
The Motley Fool June 29, 2005 Karl Thiel |
Cash In on the Future of Science With some diligence, you can ride your high school biology to biotech investing success.  |
Bio-IT World September 16, 2004 Paul King |
Growing Gains When it comes to information technology requirements, the biotech industry is unlike any other. A key enabler of efficient and effective growth is the adoption of IT strategies specific to each of four key stages.  |
Chemistry World September 12, 2008 Rebecca Trager |
NIH funds chemical biology network NIH-funded scientists will have access to the tools for rapidly screening hundreds of thousands of small molecules against many novel biological assays at lower costs than previously possible,' said the agency's director, Elias Zerhouni.  |
HHMI Bulletin Fall 2012 Robert Tjian |
President's Letter: Stabilizing Forces Recognizing the role of research professionals in today's laboratory organizations is important not only to the individuals who contribute their services but also to the research enterprise as a whole.  |
Chemistry World January 2012 |
Cultivating collaboration A new network aims to bring the power of interdisciplinary innovation to bear on global food issues.  |
Chemistry World July 6, 2012 |
Protein power Tom Muir, professor of chemistry and molecular biology, Princeton University, US, is an expert in protein engineering and its application to studying cellular signalling networks.  |
Chemistry World May 1, 2014 Ned Stafford |
Synthetic biology vision for Europe unveiled A new 'strategic vision' for synthetic biology has laid out the steps Europe needs to take in the next five to 10 year to nurture the field, with chemistry a key part of its strategy.  |
Bio-IT World November 14, 2003 Hoffer et al. |
Over the Rainbow Yet? Consolidation slows, valuations grow, and now there's hope for some biotech IPOs.  |
Bio-IT World August 2005 Maureen McDonough |
Invitrogen Launches iPath Invitrogen has unveiled a free bioinformatics and systems biology research tool that can be found on the company's Web site. iPath allows users to click their way through 2,500 human genes, 171 signal transduction pathways, and 54 metabolic pathways.  |
The Motley Fool January 30, 2007 Ralph Casale |
Molecular Devices Acquired Successful integration of companies like Molecular Devices and improvement of operating margins in the pharmaceutical contract research business unit should reward shareholders well.  |
Bio-IT World February 10, 2003 Salvatore Salamone |
Made in Manhattan A talk with the new head of the Computational Biology Center at Memorial Sloan-Kettering.  |
Chemistry World April 11, 2012 Mico Tatalovic |
Croatian scientists call for chemical reagent regulation Prominent Croatian scientists are calling for better regulation of the domestic market for laboratory chemicals and reagents as prices can be as much as 70% higher than in other European countries.  |
National Defense June 2010 Stew Magnuson |
Growing Public Interest In Genetic Science Sparks Some Bio-Security Concerns A growing movement of hobbyists who are carrying out biology experiments in garages, basements and community labs has drawn some interest from the FBI.  |
Bio-IT World March 2006 |
Bio-IT World Bio-IT 50 The 50 companies profiled here have driven and continue to drive the future of biomedical research and drug discovery: Accelrys... Affymetrix.. Apple... Becton Dickinson... BlueArc... 454 Life Sciences... etc.  |
Chemistry World September 13, 2012 Andy Merritt |
Chemical biology comes of age Historically strongest in the US, chemical biology has become increasingly important worldwide, but for many years researchers at the chemistry -- biology interface have struggled to establish their discipline  |
Pharmaceutical Executive January 1, 2006 Clinton & Wechsler |
What Ever Happened to Critical Path FDA's ambitious program to improve drug development disappeared from view almost as soon as it was announced. Suddenly, it's back, but is it here to stay?  |
Bio-IT World December 15, 2003 Zachary Zimmerman |
Learning the Language of Systems Biology Geneticist par excellence David Botstein talks about his philosophy, science, his mission for integrative science, and what he deems a success for systems biology.  |
Chemistry World June 25, 2015 Rebecca Trager |
NIH plan to get drug development unit back online The NIH has set out key milestones in its plan, including training and re-training personnel in good manufacturing practice regulations by August.  |
Bio-IT World September 9, 2002 |
Letters Frustrated in Gene Town... IT for the Biologists, by the Biologists?...  |
Pharmaceutical Executive April 1, 2012 Jill Wechsler |
Shortages and Sunshine Disclosure rules the day, as industry confronts demands to report supply problems, results of clinical trials, and payment to doctors.  |
Reason June 2005 Kerry Howley |
Scientists for Sale Innovation vs. ethics: Scientists at the NIH have discovered many things over the years, but evidently they haven't yet found a way to balance innovation and objectivity.  |
Pharmaceutical Executive March 1, 2012 Ron Cohen |
FDA's Necessary Dose of Reality There's no fast-acting salve, but there are several steps that can be taken to streamline many of the procedures at FDA. And it begins with leadership.  |
The Motley Fool July 26, 2006 Ryan Fuhrmann |
Sigma-Aldrich's Steady Growth Growth at this life science company is steady, not spectacular. With a current stock price of $67.78, the shares trade at about 17 times projected earnings.  |
The Motley Fool May 5, 2004 Brian Gorman |
Albany Molecular Gets Out-Outsourced Albany Molecular Research, provider of chemistry services to biotech and pharmaceutical clients, is suffering from the loss of business to low-cost competitors overseas.  |
Chemistry World March 19, 2007 Jessica Ebert |
Pocket-Sized PCR Machine Scientists in the US report being one step closer to designing a miniaturized, portable polymerase chain reaction machine that could be used for applications such as point-of-care diagnostics.  |
The Motley Fool January 4, 2007 Ralph Casale |
Picks and Shovels of Biotechnology Biotech investors will continue to venture into the dark mines of burgeoning pharmaceutical firms. There is certainly gold to be found in some of them, just remember to invest in some of the hardware stores of biotechnology along the way.  |
Bio-IT World August 2005 Ellen H. Julian |
Tech Expertise Singles Out Outsourcers Biopharmaceutical companies are flocking to consultants, outsourcers, and staffing firms to help with discrete clinical trial processes to gain access to advanced technologies and reduce the drain on already-scarce IT resources.  |
Chemistry World June 8, 2015 Rebecca Trager |
NIH drug manufacturing unit shut down The halt could potentially affect 46 clinical trials, and about 250 patients who are either receiving, or about to receive, products manufactured at the facility.  |
Pharmaceutical Executive June 1, 2012 Jill Wechsler |
Innovation and Collaboration A rash of "pro-innovative" approaches for testing and regulating medical products offer ways to speed more new products to market.  |
HBS Working Knowledge January 5, 2011 |
Funding Unpredictability Around Stem-Cell Research Inflicts Heavy Cost on Scientific Progress Society pays a high price for randomization of research support -- a fact that, sadly, is not recognized by the public, the media, or politicians.  |
BusinessWeek November 6, 2006 Nichola Saminather |
Biotech's Beef There is a disconnect between what universities are teaching and what biotech wants.  |
Pharmaceutical Executive September 1, 2013 Jill Wechsler |
Biopharma Innovation in Trouble? Regulators, sponsors seek more productive research strategies.  |